RYZUMVI Trademark

Trademark Overview

On Monday, October 10, 2022, a trademark application was filed for RYZUMVI with the United States Patent and Trademark Office. The USPTO has given the RYZUMVI trademark a serial number of 97626126. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Wednesday, February 12, 2025. This trademark is owned by OCUPHIRE PHARMA, INC.. The RYZUMVI trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the pharmaceutical field; consulting services in the field of pharmaceutical research and development; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
ryzumvi

General Information

Serial Number97626126
Word MarkRYZUMVI
Filing DateMonday, October 10, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateWednesday, February 12, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 5, 2023

Trademark Statements

Goods and ServicesResearch and development in the pharmaceutical field; consulting services in the field of pharmaceutical research and development; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, October 25, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameOPUS GENETICS, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressDURHAM, NC 27709
Party NameOCUPHIRE PHARMA, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressFarmington Hills, MI 48335
Party NameOCUPHIRE PHARMA, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressFarmington Hills, MI 48335

Trademark Events

Event DateEvent Description
Friday, July 28, 2023NON-FINAL ACTION WRITTEN
Thursday, October 13, 2022NEW APPLICATION ENTERED
Tuesday, October 25, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 24, 2023ASSIGNED TO EXAMINER
Friday, July 28, 2023NON-FINAL ACTION E-MAILED
Friday, July 28, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 25, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 25, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 26, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 27, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 5, 2023PUBLISHED FOR OPPOSITION
Tuesday, December 5, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 30, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 7, 2024DIVISIONAL REQUEST RECEIVED
Wednesday, May 8, 2024TEAS REQUEST TO DIVIDE RECEIVED
Monday, July 29, 2024SOU EXTENSION 1 FILED
Monday, July 29, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, May 7, 2024TEAS STATEMENT OF USE RECEIVED
Wednesday, October 23, 2024DIVISIONAL PROCESSING COMPLETE
Wednesday, October 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 23, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, October 23, 2024SOU EXTENSION 1 GRANTED
Wednesday, February 12, 2025SOU EXTENSION 2 GRANTED
Wednesday, February 12, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, October 23, 2024CORRECTED NOA E-MAILED
Friday, January 17, 2025SOU EXTENSION 2 FILED
Friday, January 17, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, February 26, 2025AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

Related Keywords

ryzumvi research scientific field development medical pharmaceutical pharmaceuticals trials information clinical